IMNI PRECISION trial protocol: a phase II, open-label, non-inferior randomized controlled trial of tailoring omission of internal mammary node irradiation for early-stage breast cancer

[1]  K. Shen,et al.  Association of 21-gene recurrence score and locoregional recurrence in early breast cancer patients. , 2022, Cancer biomarkers : section A of Disease markers.

[2]  Cheng Xu,et al.  Mapping of PET/CT based regional nodes distribution of recurrent/advanced breast cancer and comparison with current delineation atlas. , 2022, The British journal of radiology.

[3]  Cheng Xu,et al.  Practical Model to Optimize the Strategy of Adjuvant Postmastectomy Radiotherapy in T1-2N1 Breast Cancer With Modern Systemic Therapy , 2022, Frontiers in Oncology.

[4]  Hyun Soo Shin,et al.  Effect of Elective Internal Mammary Node Irradiation on Disease-Free Survival in Women With Node-Positive Breast Cancer: A Randomized Phase 3 Clinical Trial. , 2021, JAMA oncology.

[5]  H. Duan,et al.  Is it beneficial for patients with pT1‐2N1M0 breast cancer to receive postmastectomy radiotherapy? An analysis based on RecurIndex assay , 2021, International journal of cancer.

[6]  Sung-Bae Kim,et al.  Prognostic value of the 21-gene recurrence score for regional recurrence in patients with estrogen receptor-positive breast cancer , 2021, Breast Cancer Research and Treatment.

[7]  Yueping Liu,et al.  The beneficial role of Asian-based RecurIndex test in the prognostic prediction in Chinese male breast cancer patients , 2021, Scientific Reports.

[8]  R. Greil,et al.  PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2– disease: results from 1204 patients in the randomized ABCSG-8 trial , 2021, The British journal of surgery.

[9]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[10]  Jiayi Chen,et al.  Established and Validated a Novel Nomogram for Predicting Prognosis of Post-mastectomy pN0-1 Breast Cancer Without Adjuvant Radiotherapy , 2020 .

[11]  E. van Limbergen,et al.  Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial. , 2020, The Lancet. Oncology.

[12]  S. Darby,et al.  Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer , 2018, British Journal of Cancer.

[13]  D. Gaffney,et al.  Is radiation indicated for young women with early stage, node‐negative breast cancer after mastectomy? A multi‐institution, retrospective review , 2018, The breast journal.

[14]  M. Morrow,et al.  Are there patients with T1 to T2, lymph node‐negative breast cancer who are “high‐risk” for locoregional disease recurrence? , 2017, Cancer.

[15]  E. Huang,et al.  An Eighteen-Gene Classifier Predicts Locoregional Recurrence in Post-Mastectomy Breast Cancer Patients , 2016, EBioMedicine.

[16]  H. Kang,et al.  Identification of Risk Factors for Locoregional Recurrence in Breast Cancer Patients with Nodal Stage N0 and N1: Who Could Benefit from Post-Mastectomy Radiotherapy? , 2015, PloS one.

[17]  Laurence Collette,et al.  Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer. , 2015, The New England journal of medicine.

[18]  EBCTCG (Early Breast Cancer Trialists' Collaborati.  Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials , 2014, The Lancet.

[19]  E. Aleknavičius,et al.  Postmastectomy internal mammary nodal irradiation: a long-term outcome. , 2014, Medicina.

[20]  M. Tsou,et al.  Validating a prognostic scoring system for postmastectomy locoregional recurrence in breast cancer. , 2013, International journal of radiation oncology, biology, physics.

[21]  R Peto,et al.  Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials , 2011, The Lancet.

[22]  Barbara L. Smith,et al.  Breast PATTERNS AND RISK FACTORS OF LOCOREGIONAL RECURRENCE IN T 1T 2 NODE NEGATIVE BREAST CANCER PATIENTS TREATED WITH MASTECTOMY : IMPLICATIONS FOR POSTMASTECTOMY RADIOTHERAPY , 2011 .

[23]  S. Paik,et al.  Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. West,et al.  Gene expression predictors of breast cancer outcomes , 2003, The Lancet.

[25]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[26]  J. Peterse,et al.  Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.